Evénements Archive - Page 3 of 5 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
Evénements Archive - Page 3 of 5 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • Lusvertikimab (OSE-127)
    • Pegrizeprument (FR104)
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Regulated information
    • Financial documents
    • General Shareholders’ meetings
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Agenda
    • Press Releases
  • Contact
en
  • fr

Projects Archives

September 2023

European MidCap Event, 23rd Edition

September 2023

H.C. Wainwright 25th Annual Global Investment Conference

September 2023

23RD ANNUAL BIOTECH IN EUROPE FORUM FOR GLOBAL PARTNERING & INVESTMENT

December 2022

Degroof Petercam Healthcare Conference

December 2022

J.P. Morgan Healthcare Conference

November 2022

Invest Securities BioMed Forum

September 2022

HealthTech Innovation Days

September 2022

Amsterdam Midcap Event

September 2022

H.C. Wainwright 24th Annual Global Investment Conference

June 2022

Conference call for analysts to comment the updated data presented at the 2022 ASCO meeting

  • Précédent
  • 1
  • 2
  • 3
  • 4
  • 5
  • Suivant

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris